Compounds > bdp 12
Page last updated: 2024-09-04

bdp 12 and Disease Models, Animal

bdp 12 has been researched along with Disease Models, Animal in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (75.00)29.6817
2010's0 (0.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV1
Broberg, BV; Dias, R; Glenthøj, BY; Larsen, DB; Olsen, CK1
Baumbarger, P; Bleakman, D; Gates, M; Hicks, CA; Lodge, D; Murray, TK; Nisenbaum, ES; O'Neill, MJ; Ogden, AM; Robinson, CS; Siuda, E; Skolnick, P; Vandergriff, JL; Ward, MA; Whalley, K; Zimmerman, DM1
Blanchet, PJ; Chase, TN; Konitsiotis, S; Lamers, E; Verhagen, L1

Other Studies

4 other study(ies) available for bdp 12 and Disease Models, Animal

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection

2020
Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia--sub-chronic and early postnatal PCP treatment in attentional set-shifting.
    Psychopharmacology, 2009, Volume: 206, Issue:4

    Topics: Animals; Antipsychotic Agents; Attention; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Indoles; Male; Phencyclidine; Piperidines; Rats; Schizophrenia

2009
LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 306, Issue:2

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amides; Animals; Biphenyl Compounds; Cells, Cultured; Corpus Striatum; Dioxoles; Disease Models, Animal; Excitatory Amino Acid Agonists; GAP-43 Protein; Hippocampus; Humans; Male; Neurons; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Piperidines; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, Glutamate; Substantia Nigra

2003
AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys.
    Neurology, 2000, Apr-25, Volume: 54, Issue:8

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzodiazepines; Dioxoles; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Dyskinesia, Drug-Induced; Excitatory Amino Acid Antagonists; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Parkinson Disease, Secondary; Piperidines; Receptors, AMPA; Severity of Illness Index

2000